Immunogenic Cell Death-Based Cancer Vaccines

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Cancer immunotherapy has advanced significantly but faces challenges with immunologically "cold" tumors.
• Immunogenic cell death (ICD) is a promising strategy to overcome these limitations by activating anti-tumor immunity.

Purpose of the Study:

• To propose and review the concept of "ICD-based cancer vaccines" for enhancing cancer immunotherapy.
• To summarize current sources of ICD-based cancer vaccines and discuss associated challenges.

Main Methods:

• This review synthesizes existing research on immunogenic cell death and its application in cancer vaccines.
• Analysis of how dying cancer cells release danger-associated molecular patterns (DAMPs) and neoantigens to trigger adaptive immunity.

Main Results:

• ICD induction effectively mimics the process of cancer vaccination, creating a "cancer vaccine-like effect".
• Dying cancer cells under specific stress release DAMPs and neoantigens, crucial for initiating anti-tumor immune responses.

Conclusions:

• ICD-based cancer vaccines represent a novel approach to activate anti-tumor immunity, particularly in "cold" tumors.
• Further research into ICD sources and overcoming challenges is needed to fully realize the potential of ICD-based cancer vaccines in immunotherapy.